A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas

Trial Profile

A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2017

At a glance

  • Drugs AMP 514 (Primary) ; Inebilizumab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top